Rehmann Capital Advisory Group’s Abiomed Inc ABMD Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$9.61K	Sell	54 -369	-87%	-$79.8K	﹤0.01%	1061
2019 Q2	$110K	Buy	423 +370	+698%	+$98.2K	0.01%	584
2019 Q1	$15.1K	Hold	53	–	–	﹤0.01%	1202
2018 Q4	$17.2K	Hold	53	–	–	﹤0.01%	900
2018 Q3	$23.8K	Sell	53 -1	-2%	-$394	﹤0.01%	1062
2018 Q2	$22.1K	Buy	54 +1	+2%	+$362	﹤0.01%	1070
2018 Q1	$15K	Sell	53 -1,108	-95%	-$281K	﹤0.01%	1182
2017 Q4	$218K	Sell	1,161 -40	-3%	-$7.47K	0.04%	357
2017 Q3	$202K	Buy	+1,201	New	+$182K	0.04%	362

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Rehmann Capital Advisory Group's ABMD Position: Q3 2019 in Review

Rehmann Capital Advisory Group reduced its Abiomed Inc (ABMD) stake by 87% in Q3 2019, selling an estimated $79.8K and leaving 54 shares worth $9.61K. The position accounts for ﹤0.01% of the portfolio, ranked #1061.

Rehmann Capital Advisory Group first reported a position in ABMD in Q3 2017 and has held it in 9 quarters since. The position peaked at $218K in Q4 2017. 443 funds tracked by Wall St. Rank hold ABMD as of Q3 2019.

Rehmann Capital Advisory Group held 54 shares of Abiomed Inc worth $9.61K as of Q3 2019.
Rehmann Capital Advisory Group sold 369 Abiomed Inc shares in Q3 2019, an estimated $79.8K.
Abiomed Inc made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1061 holding.
Rehmann Capital Advisory Group first reported a position in Abiomed Inc in Q3 2017 and has held it in 9 quarters since.
Rehmann Capital Advisory Group's Abiomed Inc position peaked at $218K in Q4 2017.
443 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.